Cited by

• Sorafenib-Loaded PLGA Carriers for Enhanced Drug Delivery and Cellular Uptake in Liver Cancer Cells.

  Caputo TM, Cusano AM, Principe S, Cicatiello P, Celetti G, Aliberti A, Micco A, Ruvo M, Tagliamonte M, Ragone C, Minopoli M, Carriero MV, Buonaguro L, Cusano A. Caputo TM, et al. Int J Nanomedicine. 2023 Jul 26;18:4121-4142. doi: 10.2147/IJN.S415968. eCollection 2023. Int J Nanomedicine. 2023. PMID: 37525693 Free PMC article.
• Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma.

  Tseng HC, Xiong W, Badeti S, Yang Y, Ma M, Liu T, Ramos CA, Dotti G, Fritzky L, Jiang JG, Yi Q, Guarrera J, Zong WX, Liu C, Liu D. Tseng HC, et al. Nat Commun. 2020 Sep 23;11(1):4810. doi: 10.1038/s41467-020-18444-2. Nat Commun. 2020. PMID: 32968061 Free PMC article.
• Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging.

  Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, Mazzarino MC, Donia M, Fagone P, Malaponte G, Nicoletti F, Libra M, Milella M, Tafuri A, Bonati A, Bäsecke J, Cocco L, Evangelisti C, Martelli AM, Montalto G, Cervello M, McCubrey JA. Steelman LS, et al. Aging (Albany NY). 2011 Mar;3(3):192-222. doi: 10.18632/aging.100296. Aging (Albany NY). 2011. PMID: 21422497 Free PMC article. Review.
• Gene expression-based chemical genomics identifies potential therapeutic drugs in hepatocellular carcinoma.

  Chen MH, Yang WL, Lin KT, Liu CH, Liu YW, Huang KW, Chang PM, Lai JM, Hsu CN, Chao KM, Kao CY, Huang CY. Chen MH, et al. PLoS One. 2011;6(11):e27186. doi: 10.1371/journal.pone.0027186. Epub 2011 Nov 7. PLoS One. 2011. PMID: 22087264 Free PMC article.
• The STORM trial and beyond: narrowing the horizon of adjuvant sorafenib for postoperative hepatocellular carcinoma.

  Zhong JH. Zhong JH. Tumour Biol. 2015 Nov;36(11):8271-2. doi: 10.1007/s13277-015-4279-0. Tumour Biol. 2015. PMID: 26499777 No abstract available.